

Our ref: FOI 1276

Information Governance Team

24th October 2022

SOUTHERN HEALTH & SOCIAL CARE TRUST FREEDOM OF INFORMATION RESPONSE 1276

Q1. How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:

- Adalimumab - Humira
- Adalimumab Biosimilar
- Filgotinib
- Golimumab
- Infliximab - Remicade
- Infliximab Biosimilar
- Ozanimod
- Tofacitinib
- Ustekinumab
- Vedolizumab

• Adalimumab - Humira	9
• Adalimumab Biosimilar	192
• Filgotinib	0
• Golimumab	<5
• Infliximab - Remicade	0
• Infliximab Biosimilar	78
• Ozanimod	0
• Tofacitinib	6
• Ustekinumab	86
• Vedolizumab	89

Q2 If you are able to link patient treatment to a disease, could you please provide the number of patients treated in the last 3 months for Ulcerative Colitis ONLY with the following biologic drugs:

- Adalimumab - Humira
- Adalimumab Biosimilar
- Filgotinib
- Golimumab
- Infliximab - Remicade
- Infliximab Biosimilar
- Ozanimod
- Tofacitinib
- Ustekinumab
- Vedolizumab

• Adalimumab - Humira	<5
• Adalimumab Biosimilar	69
• Filgotinib	0
• Golimumab	<5
• Infliximab - Remicade	0
• Infliximab Biosimilar	37
• Ozanimod	0
• Tofacitinib	6
• Ustekinumab	19
• Vedolizumab	52

The Trust has a legal duty to protect patient confidentiality and, in line with this duty, the figure <5 has been provided where figures are very low. This is because of the potential risk of identification of an individual. In reaching this decision the Trust has taken into account the small geographical area which the Trust serves and the sensitivity of the information requested. In addition the Trust has taken into account the fact that all information disclosed in response to an FOI is disclosed to the 'world at large' and is published on the Trust website.

S 40 (2) (third party information) of the Freedom of Information Act 2000 has been applied to exempt the redacted information from disclosure. The Trust does not consider the disclosure of the redacted information to be fair to the individuals concerned as there is the potential risk of identification of an individual(s) which they would not expect, and which would therefore breach the fairness element of the first principle of the Data Protection Act 2018.